DAFNA Capital Management LLC increased its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 56.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 393,083 shares of the company's stock after acquiring an additional 142,500 shares during the quarter. DAFNA Capital Management LLC owned approximately 1.19% of Lexeo Therapeutics worth $2,586,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Altium Capital Management LLC acquired a new position in Lexeo Therapeutics during the fourth quarter worth $2,665,000. Privium Fund Management B.V. bought a new stake in Lexeo Therapeutics during the 4th quarter worth about $909,000. ADAR1 Capital Management LLC raised its holdings in shares of Lexeo Therapeutics by 196.5% in the 4th quarter. ADAR1 Capital Management LLC now owns 169,505 shares of the company's stock valued at $1,115,000 after purchasing an additional 112,339 shares during the period. Bridgeway Capital Management LLC acquired a new stake in Lexeo Therapeutics in the 4th quarter valued at about $428,000. Finally, Walleye Capital LLC bought a new position in Lexeo Therapeutics during the fourth quarter worth about $407,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have recently commented on LXEO. HC Wainwright reiterated a "buy" rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Royal Bank of Canada cut their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Finally, Chardan Capital lowered their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Lexeo Therapeutics currently has an average rating of "Buy" and a consensus target price of $21.80.
Check Out Our Latest Analysis on LXEO
Lexeo Therapeutics Stock Up 9.1%
Shares of LXEO traded up $0.24 during trading hours on Tuesday, reaching $2.87. The stock had a trading volume of 521,575 shares, compared to its average volume of 464,713. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $3.06 and a 200 day simple moving average of $5.09. Lexeo Therapeutics, Inc. has a 12 month low of $1.45 and a 12 month high of $19.50. The company has a market capitalization of $95.28 million, a price-to-earnings ratio of -0.91 and a beta of 1.27.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19). Equities research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.
Lexeo Therapeutics Profile
(
Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
See Also
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
